Published date: 30 September 2022

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 19 August 2022, 12pm

Contract summary

Industry

  • Business and management consultancy and related services - 79400000

Location of contract

United Kingdom

Value of contract

£30,000

Procurement reference

NCL001-DN621813-23144958

Published date

30 September 2022

Closing date

19 August 2022

Closing time

12pm

Contract start date

18 September 2022

Contract end date

30 June 2023

Contract type

Service contract

Procedure type

Restricted procedure

A two-stage procedure, where the first stage is used to select suppliers, who are then invited to bid in the second stage.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.

The initial brief of the executive will be to:
Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;

Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board

Phase (3) January 2023-March 2023 - a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;
b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO.
c. Provide to the University of Bath all matters necessary for Research England reporting requirements.

Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding

Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.

Award information

Awarded date

21 September 2022

Contract start date

26 September 2022

Contract end date

30 June 2023

Total value of contract

£30,000

This contract was awarded to 1 supplier.

Cambridge Drug Discovery

Address

35 Tunwells Lane
Great Shelford
Cambridge
Cambridgeshire
United Kingdom
CB22 5LJ

Reference

None

Supplier is SME?

Yes

Supplier is VCSE?

No

About the buyer

Contact name

Natalie Morton

Address

Newcastle University
Procurement Services, Kingsgate
Newcastle
NE1 7RU
United Kingdom

Telephone

+44 1912086396

Email

natalie.morton@ncl.ac.uk

Website

https://www.ncl.ac.uk